

ECNP Research and Scholarship
Foundation

Annual Report 2021

ECNP Research and Scholarship Foundation

Annual Report 2021

1. About ECNP R&S	3
2. Activities 2021	4
3. Financial Overview	6
Financial statements	6
4. Future Outlook	8



The ECNP Research and Scholarship Foundation is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP R&S

The ECNP Research and Scholarship Foundation (ECNP R&S) is an independent foundation that exists to promote high-quality experimental and clinical research and education in applied and translational neuroscience, with a view to stimulating the development of better treatments for those suffering disorders of the brain.

The object of the Foundation is to create a framework for the organisation of the annual congresses of ECNP. It is a non-profit making body.

Address: Daltonlaan 400, 3584 BK Utrecht

E-mail: secretariat@ecnp.eu

Website: <https://www.ecnp.eu>

RSIN: 807967087

Dutch Chamber of Commerce number: 41215196

Dutch TAX number: NL807967087B01

ANBI: ECNP R&S is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

Board

Gitte Moos Knudsen
President
Copenhagen University
Hospital, Denmark

Catherine Harmer
Treasurer
University of Oxford
United Kingdom

Suzanne Dickson
Secretary
University of Göteborg
Sweden

The members of the board receive no remuneration for their role.

Alexander Schubert
Executive Director
The Netherlands

2. Activities 2021

To execute its mission to support European applied and translational neuroscience ECNP R&S performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

In 2021 the following programmes were delivered:

Scientific and educational meetings

- **ECNP Seminar in Neuropsychopharmacology**

4-5 February 2021 – virtual

These high-impact training courses are offered for developing-economy countries, to enhance knowledge and skills in a concentrated learning environment with local and international experts. In 2021 one Seminar was held, with participants from Slovenia. Funded by ECNP R&S.

- **ECNP Workshop for Early Career Scientists in Europe**

3-5 March 2021 – virtual

The Workshop offers 100 European early career scientists three days of intense interaction with research leaders discussing the latest advances and perspectives in translational neuroscience. Funded by ECNP R&S.

- **ECNP New Frontiers Meeting in Digital Health**

8-9 March 2021 – virtual

A unique platform for focused, high-level exchange between scientists, industry leaders and regulators at the intersection of research science and new treatment development. The 2021 explored a range of topics, from digital therapeutics, to regulatory challenges posed by digital biomarkers and therapeutic, and pitfalls and potential of optimising clinical trials with digital tools. Funded by ECNP R&S.

- **ECNP School of Child and Adolescent Neuropsychopharmacology**

30 June-2 July 2021 – virtual

The School offers European early career clinicians a focused programme of intensive training in neuropsychopharmacology for children and adolescents. Funded by ECNP R&S.

- **ECNP School of Neuropsychopharmacology**

30 June-2 July 2021 – virtual

The School offers European early career clinicians immersion in the fundamentals of neuropsychopharmacology, from good clinical practice and the optimal treatment and algorithms to the use of medications in individual indications. Funded by ECNP R&S.

- **ECNP Workshop on Clinical Research Methods**

3-5 November 2021, Barcelona, Spain

The Workshop offers 40 European early career scientists three days of training on research methodology and critical approaches to the scientific literature for early career scientists. Tuition, registration, accommodation and catering was funded by ECNP R&S.

- **ECNP Small Private Online Course (SPOC): 'Introduction to Neuropsychopharmacology'**

This online training course prepares early career clinicians for ECNP R&S educational activities, seminars, schools and internships offers modules covering neuroanatomy, neurophysiology, neurogenetics, psychopharmacology, immunology and statistics. Funded by ECNP R&S.

Awards

- **ECNP Citation Prize**

Awarded to the most-cited research paper in the ECNP journal, *European Neuropsychopharmacology* (ENP) in the preceding two years, the award recognises and encourages impactful original research. The 2021 winner was Christiaan H. Vinkers et al., 'Stress resilience during the coronavirus pandemic,' *European Neuropsychopharmacology* 35, 2020, 12-16. Funded by ECNP R&S.

- **Negative Results Prize in Clinical Neuroscience**

The award recognises those who have made exceptional contributions to CNS treatment development by publishing clinical research with negative findings and helping to advance long-term treatment development. The 2021 winner was C. G. Abdallah et al., 'Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin,' *Neuropsychopharmacology* 45, 2020, 990-997. Funded by ECNP R&S in collaboration with Cohen Veterans Bioscience.

Other major initiatives

- **Neuroscience-based Nomenclature (NbN)**

This international collaborative venture, led by ECNP, is working to develop a new nomenclature for psychotropic medications grounded in the latest advances in brain science. Unique in its aims and unprecedented in its scope, in 2021 the initiative's NbN app and NbN-ca app for child and adolescent treatments reached a total of 88,000 downloads worldwide, with translations in French, Spanish and Chinese. Funded by ECNP R&S.

- **Neuroscience Applied**

In 2021 ECNP R&S and Elsevier B.V. came to an agreement over the launch of a fully open-access scientific journal, targeting the intersection between neuroscience, applications and new treatment horizons. The journal will encompass original basic, clinical and integrative research that has translational relevance for mental health, focusing especially on mechanisms of disorders, biological, psychological and social treatments, prevention and policies that apply a neuroscientific approach to brain disorders. It will officially begin operations in early 2022. The journal is fully owned by ECNP R&S

3. Financial Overview

ECNP R&S's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Capital preservation – at agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP R&S invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

The unexpected buoyancy of the capital markets in 2021 delivered unforeseen investment returns for ECNP R&S. The additional returns will be used to pursue the goals mentioned above (See Future Plans), as well as to prepare for what is expected to be a market downturn.

Financial statements

Balance sheet as at 31 December 2021 (after appropriation of profit/losses)

	31-12-2021		31-12-2020	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		11,018,368		11,915,000
CURRENT ASSETS				
Accounts receivable				
Debtors	14,134		85,137	
Amounts owed by congress foundations	190,818		258,079	
Amounts owed by other foundations	-		12,797	
Taxes	412		1,708	
Other receivables	72,367		127	
Prepayments and accrued income	6,472		-	
		284,203		357,848
Bank deposits		2,162,458		1,308,419
		2,446,661		1,666,267
		<u>13,465,029</u>		<u>13,581,267</u>

	31-12-2021		31-12-2020	
	€	€	€	€
RESERVES, FUNDS AND LIABILITIES				
RESERVES AND FUNDS				
Other reserves		13,407,009		13,489,110
CURRENT LIABILITIES				
Trade creditors	35,268		58,444	
Other liabilities	22,752		33,713	
		58,020		92,157
		<u>13,465,029</u>		<u>13,581,267</u>

Statement of income and expenditure 2021

	Balance 2021	Balance 2020
	€	€
Income		
Proceeds fundraising	185,641	688,411
Income NSA	33,500	-
NbN books	16,932	102,227
Interest and similar income	103,368	668,208
Total income	<u>339,441</u>	<u>1,458,846</u>
Expenses		
Donations	-	1,000,000
Meetings	40,070	208,259
Other activities	98,999	106,958
Other expenses	274,115	306,174
Interest and similar charges	8,358	14,337
Total expenses	<u>421,542</u>	<u>1,635,728</u>
Result	<u>-82,101</u>	<u>-176,882</u>
Appropriation of result		
Other reserves	<u>-82,101</u>	<u>-176,882</u>

4. Future Outlook

ECNP R&S funds amongst the largest suite of scientific and educational activities in neuroscience of any non-institutional organisation in Europe:

- More than 20 scientific meetings held every year
 - Spanning all aspects of scientific, educational, and regulatory dialogue
 - Bringing together researchers and clinicians from over 100 countries for fruitful scientific exchange
- 400 young scientists trained every year
 - Paid for by ECNP R&S

In the coming year, ECNP R&S's plans will be defined by a variety of major goals:

1. Strategic reassessment

A broad-scale reassessment was initiated in 2021 of ECNP R&S's impact in the community it serves and the translational neuroscience field more generally. Two initiatives were established to drive this reassessment:

- The *Innovation Task Force* to explore how ECNP R&S's programmes and activities should be adapted to accommodate the new ways science is increasingly being exchanged, communicated, taught and published, and how ECNP R&S programmes and activities can be scaled to respond to the full breadth of the need they are designed to serve.
- The *Sustainability Task Force* to explore how ECNP R&S's environmental footprint can be resized to meet sustainability targets.

2. The development of online delivery platforms

The corona crisis compelled ECNP R&S to develop, at speed, an online delivery strategy. The successes of the virtual meetings organised and the opportunities they offer to expand ECNP's audience, combined changing consumer habits as a result both of the corona epidemic and climate change, has made online delivery an important new priority.

3. The expansion of the publication portfolio

Responding to the evolving nature of the science ECNP represents, in which new developments continue to expand ECNP's scientific remit and funders and researchers (especially in Europe) increasingly expect that research be freely available, ECNP R&S has taken the step of launching an open-access journal, *Neuroscience Applied*, to operate in parallel with *European Neuropsychopharmacology*.

A new journal is a major undertaking and it is expected that building *Neuroscience Applied*'s profile, author community and impact factor will be significant challenges, and that the journal will be an important financial focus of ECNP R&S's for the coming years.